Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is experiencing upward revisions in its FY26 earnings per share estimates, reflecting a positive adjustment due to a higher share count and improving business prospects. The anticipated approval of the MyoVista device, combined with the ongoing rollout of the MyoVista Insights cloud platform and the expected FDA approval of its first diagnostic algorithm in early 2026, positions the company for significant market potential. Additionally, the establishment of a new price target derived from net present value analysis indicates robust growth opportunities, suggesting a favorable outlook for the company's financial performance.

Bears say

HeartSciences Inc. is facing a significant downturn in its financial outlook, reflected in a dramatic decrease in projected revenue for FY2026, which has been revised down to $0.1 million from a previous estimate of $1.2 million due to FDA-related delays. Additionally, the company is burdened by substantial risks, including balance sheet and liquidity concerns, regulatory approval challenges, and competition in the healthcare sector. The combination of these operational setbacks and uncertainty in market conditions has contributed to a negative perspective on the company's potential for growth and financial stability.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.